CA2531223A1 - Compositions containing prodrugs of florfenicol and methods of use - Google Patents

Compositions containing prodrugs of florfenicol and methods of use Download PDF

Info

Publication number
CA2531223A1
CA2531223A1 CA002531223A CA2531223A CA2531223A1 CA 2531223 A1 CA2531223 A1 CA 2531223A1 CA 002531223 A CA002531223 A CA 002531223A CA 2531223 A CA2531223 A CA 2531223A CA 2531223 A1 CA2531223 A1 CA 2531223A1
Authority
CA
Canada
Prior art keywords
florfenicol
prodrug
composition
butyrate
hexanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002531223A
Other languages
English (en)
French (fr)
Inventor
Yerramilli Murthy
Robert H. Suva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idexx Laboratories Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2531223A1 publication Critical patent/CA2531223A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002531223A 2003-07-18 2004-06-29 Compositions containing prodrugs of florfenicol and methods of use Abandoned CA2531223A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/623,114 US7439268B2 (en) 2003-07-18 2003-07-18 Compositions containing prodrugs of florfenicol and methods of use
US10/623,114 2003-07-18
PCT/US2004/021260 WO2005009429A1 (en) 2003-07-18 2004-06-29 Compositions containing prodrugs of florfenicol and methods of use

Publications (1)

Publication Number Publication Date
CA2531223A1 true CA2531223A1 (en) 2005-02-03

Family

ID=34063306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002531223A Abandoned CA2531223A1 (en) 2003-07-18 2004-06-29 Compositions containing prodrugs of florfenicol and methods of use

Country Status (6)

Country Link
US (4) US7439268B2 (enExample)
EP (2) EP1651202A4 (enExample)
JP (1) JP2006528177A (enExample)
AU (1) AU2004258876B2 (enExample)
CA (1) CA2531223A1 (enExample)
WO (1) WO2005009429A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
JP4719160B2 (ja) 2003-12-23 2011-07-06 シェーリング−プラウ・リミテッド 改善された水溶性を有するフロルフェニコールプロドラッグ
US7361689B2 (en) 2003-12-31 2008-04-22 Schering-Plough Animal Health Corporation Antibacterial 1-(4-mono- and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoroproponals and preparation thereof
US7276257B2 (en) * 2005-07-22 2007-10-02 The Hong Kong University Of Science And Technology Schisandrin B preparation
WO2007067729A2 (en) 2005-12-09 2007-06-14 University Of Georgia Research Foundation, Inc. Microbial vaccine and vaccine vector
US8119667B2 (en) * 2005-12-29 2012-02-21 Schering-Plough Animal Health Corporation Carbonates of fenicol antibiotics
CN101605756A (zh) * 2006-12-13 2009-12-16 先灵-普劳有限公司 氟苯尼考及其类似物的水溶性前药
WO2008076261A2 (en) * 2006-12-13 2008-06-26 Schering-Plough Ltd. Water-soluble phenicol prodrugs in a lipophilic vehicle system
PE20091171A1 (es) * 2007-12-14 2009-08-03 Schering Plough Ltd Proceso para recuperar florfenicol y analogos de florfenicol
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
BRPI1008745A2 (pt) 2009-02-05 2019-09-17 Tokai Pharmaceuticals Inc pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
CN105682662A (zh) 2013-03-14 2016-06-15 马里兰大学巴尔的摩校区 雄激素受体减量调节剂及其用途
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
CN104490882A (zh) * 2014-11-29 2015-04-08 郑州后羿制药有限公司 一种治疗鸭传染性浆膜炎疾病的中兽药及其制备方法
CN105111234B (zh) * 2015-09-23 2017-05-17 河北远征禾木药业有限公司 一种氟苯尼考磷酸酯的合成方法
CN108096191A (zh) * 2017-12-29 2018-06-01 河北利华药业有限公司 氟苯尼考预混剂及其制备方法
CN110787131B (zh) * 2019-12-13 2022-04-01 河北远征药业有限公司 一种氟苯尼考可溶性粉制剂的制备方法
WO2021207647A1 (en) * 2020-04-09 2021-10-14 Computational International LLC Small molecule drugs as targeted therapeutics
CN111393341A (zh) * 2020-05-07 2020-07-10 中国农业大学 一种水溶性氟苯尼考氨基酸盐的制备方法
CN112345661B (zh) * 2020-10-21 2022-11-15 北京精益捷检测科技有限公司 一种兽药黄栀花口服液中氟苯尼考含量的测定方法
CN113416304B (zh) * 2021-06-22 2022-07-29 四川永诺生物科技有限公司 一种四臂聚乙二醇琥珀酸氟苯尼考化合物的制备方法及应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235692A (en) * 1972-01-24 1980-11-25 Townsend Douglas W Electrolytic apparatus
ES8104203A1 (es) * 1979-02-05 1981-04-16 Schering Corp Un procedimiento para la preparacion de un compuesto d-(treo-1-aril-2-acilamido-3-fluor-1-propanol
US4235892A (en) * 1979-02-05 1980-11-25 Schering Corporation, Patent Dept. 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor
US4361557A (en) * 1980-01-28 1982-11-30 Schering Corporation 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
IT1173213B (it) 1984-02-03 1987-06-18 Zambon Spa Procedimento per fluorurare alcuni derivati dall'1l-fenil-2-ammino-1,3-propandiolo e loro intermedi
US4718800A (en) 1986-04-18 1988-01-12 General Signal Corporation Stanchion
FR2608607B1 (fr) * 1986-12-23 1989-04-28 Sanofi Sa Procede de preparation de thienylethylamines et dithienylethylamines ainsi obtenues
US5807830A (en) * 1987-12-30 1998-09-15 Cytoven J.V. Method for treatment of purulent inflammatory diseases
CA1267043A (en) * 1988-03-23 1990-03-27 Ernest J. Nagy Applicator device
US4876352A (en) 1988-09-14 1989-10-24 Schering Corporation Pressurized fluorination of hydroxy alkyl groups
US5574020A (en) 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
US5082883A (en) * 1990-03-12 1992-01-21 Eastman Kodak Company Reduced viscosity polyblends of polyester and epoxy resins
IT1240676B (it) * 1990-04-24 1993-12-17 Agrimont Spa Composizioni ad attivita' erbicida
US5082863A (en) 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
CZ286239B6 (cs) * 1990-10-25 2000-02-16 Schering Corporation Způsob přípravy florfenikolu, jeho analogy a oxazolinové meziprodukty
US5158948A (en) * 1990-11-16 1992-10-27 Abbott Laboratories Tetracyclic spirobenzazepine dopamine antagonists
US5476854A (en) 1991-11-27 1995-12-19 Sepracor Inc. Methods and compositions for treating bacterial infection using optically pure (R)-lomefloxacin
US5883115A (en) 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
US5352832A (en) * 1992-12-18 1994-10-04 Schering Corporation Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates
US6110905A (en) 1994-07-09 2000-08-29 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
CA2176298C (en) 1995-06-27 2009-01-27 Dennis D. Copeland A single high dose fluoroquinolone treatment
US6310053B1 (en) 1995-07-05 2001-10-30 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US5723447A (en) 1996-07-02 1998-03-03 Rhone Merieux, Inc. Water miscible erythromycin solutions
US5958888A (en) 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions
US5663361A (en) 1996-08-19 1997-09-02 Schering Corporation Process for preparing intermediates to florfenicol
UA51730C2 (uk) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
US5755506A (en) * 1996-10-15 1998-05-26 Ray; Eric A. Illuminated badge
SE511313C2 (sv) * 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
US6239112B1 (en) 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
US5977133A (en) * 1998-08-19 1999-11-02 Abbott Laboratories Pyridone antibiotic with improved safety profile
US7131136B2 (en) * 2002-07-10 2006-10-31 E-Watch, Inc. Comprehensive multi-media surveillance and response system for aircraft, operations centers, airports and other commercial transports, centers and terminals
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6576702B2 (en) 2000-07-20 2003-06-10 Noveon Ip Holdings Corp. Plasticized waterborne polyurethane dispersions and manufacturing process
US7332457B2 (en) * 2000-09-18 2008-02-19 Honeywell International Inc. Agricultural chemical suspensions
US6787568B1 (en) * 2000-11-27 2004-09-07 Phoenix Scientific, Inc. Antibiotic/analgesic formulation and a method of making this formulation
AU2002254616B2 (en) * 2001-04-11 2007-09-06 Idenix (Cayman) Limited Phenylindoles for the treatment of HIV
IL163749A0 (en) * 2002-03-08 2005-12-18 Schering Plough Ltd Novel florfenicol-type antibiotics
US20040082530A1 (en) * 2002-04-11 2004-04-29 Schmaljohn Connie S. Nucleic acid immunization
US6790867B2 (en) 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
UA82359C2 (uk) * 2003-04-03 2008-04-10 Schering Plough Ltd Композиція (варіанти) і спосіб лікування мікробних і паразитних інфекцій у великої рогатої худоби і інших тварин
US6880956B2 (en) 2003-07-31 2005-04-19 A L Lightech, Inc. Light source with heat transfer arrangement
JP4719160B2 (ja) 2003-12-23 2011-07-06 シェーリング−プラウ・リミテッド 改善された水溶性を有するフロルフェニコールプロドラッグ

Also Published As

Publication number Publication date
AU2004258876A1 (en) 2005-02-03
JP2006528177A (ja) 2006-12-14
EP1651202A4 (en) 2006-08-02
US7786167B2 (en) 2010-08-31
EP2181706A3 (en) 2010-10-06
AU2004258876B2 (en) 2009-02-26
US7662861B2 (en) 2010-02-16
US20080090912A1 (en) 2008-04-17
WO2005009429A1 (en) 2005-02-03
US20050014828A1 (en) 2005-01-20
US7439268B2 (en) 2008-10-21
US20080306152A1 (en) 2008-12-11
EP1651202A1 (en) 2006-05-03
US20070142468A1 (en) 2007-06-21
EP2181706A2 (en) 2010-05-05

Similar Documents

Publication Publication Date Title
US7786167B2 (en) Compositions containing prodrugs of florfenicol and methods of use
CA2102454C (fr) Derives de l'erythromycine, leur procede de preparation, leur application comme medicaments
JP2006528177A5 (enExample)
JPH0529235B2 (enExample)
AU2004210714B2 (en) Medicament for inhibiting tumour growth
NZ210606A (en) Acetyl erythromycin stearate, preparation and compositions
FR2617171A1 (fr) Nouveaux derives de la somatostatine, leur preparation et leur utilisation comme medicaments
Balant et al. Prodrugs for the improvement of drug absorption via different routes of administration
WO2023038088A1 (ja) トリスルフィド化合物を用いる、肝細胞増殖因子中のチロシン残基のニトロ化を防止する方法
CA2024728A1 (fr) Utilisation de composes anti-progestomimetiques
ES2325005T3 (es) Polisacaridos modificados que muestran un reconocimiento biologico alterado.
WO1986004816A1 (fr) Preparation d'esters de 5-fluoro-2'-desoxyuridine pour l'administration intra-arterielle
US5166328A (en) S-adenosylmethionine derivatives
FR2801055A1 (fr) Derives de beta-d-5-thioxylose, procede de preparation et utilisation en therapeutique
KR100360350B1 (ko) 어포토시스억제제
EP0024189A1 (en) Acylated laidlomycin derivatives, their preparation and compositions
CN108699060A (zh) 结合有脂肪酸的恩替卡韦衍生化合物及其药学用途
CN116966169B (zh) 姜黄素聚乙二醇聚硫化丙烯胶束在制备治疗心脏再灌注损伤药物中的应用
CH641775A5 (fr) N-(1-methyl 2-pyrrolidinyl methyl) 2,3-dimethoxy 5-methylsulfamoyl benzamide et ses derives, son procede de preparation et composition le renferment.
US6884819B1 (en) Neuropathy remedies
JP3032599B2 (ja) 長鎖カルボン酸マレイミド
FR2534588A2 (fr) Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5849756A (en) Pharmaceutical composition and method for modulating the immune reaction
CN109021228A (zh) 一种多臂型peg化尿苷三乙酸酯衍生物及其制备
FR2558467A2 (fr) Nouveau produit derive de l'acide 3-amino 2-oxo azetidine 1-sulfamique, son procede de preparation, son application comme medicament et un produit intermediaire necessaire a sa preparation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued